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Melanoma is highly resistant to conventional chemotherapeutic agents and novel therapeutic approaches are
needed. Current animal models of melanoma in animals are sub-optimal. The most commonly used homograft
model is the B16 mouse melanoma. Evaluation of potential melanoma therapies with this model is limited by the
inaccuracy of caliper measurement of subcutaneous tumors, of counting lung nodules in metastasis models, and
the indirect nature of ‘‘survival’’ curves when studying brain metastases. We have developed and characterized an
accurate, sensitive, and reproducible bioluminescent B16 melanoma model that allows for serial, real-time analyses
of tumor burden in live mice. We demonstrate that this model is applicable to subcutaneous tumors, lung met-
astases, and intracranial tumors and offers a solution to many of the limitations of previous models. As proof of
principle, we use this model to show the efﬁcacy of a live, Listeria monocytogenes vaccine expressing the me-
lanoma antigen tyrosinase-related protein-2 to protect mice against intravenous B16 melanoma challenge. Addi-
tionally, we extend our approach to include the human A375 melanoma model and are able to show in vivo
differences between sub-lines with varying metastatic potential. These models represent an accurate and repro-
ducible means for in vivo melanoma monitoring in preclinical studies.
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Animal models of melanoma are in short supply. Yet pre-
clinical studies of potential therapies for melanoma depend
on these models. Several models, including the B16 me-
lanoma model, the M3 DBA/2 melanoma model (Palamara
et al, 2004), and the H-rasV12G tetracycline-inducible mod-
el (Chin et al, 1999) have been developed in immunocom-
petent mice. Additionally, in immunocompromised animals,
human xenograft melanoma models have been devel-
oped—including the well-studied A375 human melanoma
model in severe combined immunodeficiency mice (SCID)
mice. These models vary in their utility for evaluating genetic
influences on melanoma, potential direct tumor therapies,
or potential immunotherapies. Models involving immuno-
compromised animals are not applicable to study immune-
based therapies. All of these models are, however, limited in
the ability to monitor tumor burden in animals, especially for
small tumors. Quantification of tumor progression in live
animals is limited by several factors including the lower
limits of detection, the lack of precision when measuring
subcutaneous tumors with calipers, difficulty in identifying
metastatic foci in the lungs, and the obvious challenges of
evaluating brain metastases and intracranial tumors.
Specifically, for subcutaneous tumors, the lower limits of
detection using caliper measurement are problematic. Al-
though difficult to know exactly, a palpable subcutaneous
tumor may first be detectable only when well over 106 cells
are present. Complete clearance of tumors is, however, an
important endpoint that cannot be determined at this level
of sensitivity. Another issue relevant to serial monitoring of
subcutaneous tumors is that central necrosis, ulceration, or
therapy-induced apoptosis may not be fully accounted for
by gross tumor measurements. For these reasons, a tumor
monitoring system that is more sensitive and quantifies only
live cells would be a valuable tool.
One of the current models for metastasis of melanoma
and other tumors is lung tumor formation after intravenous
tail vein injection of tumor cells. Although this model does
not incorporate all the naturally occurring steps involved in
metastasis, it has historically been used to evaluate chang-
es in metastatic potential of melanoma cells or therapies
affecting metastasis (Collisson et al, 2003a, b). In this mod-
el, B16 melanoma tumors are usually quantified by counting
black tumors on the outside of excised lungs. This meth-
odology suffers from the following deficiencies: that the lung
tumors are of varying sizes and this is not incorporated into
the ‘‘metastatic foci number’’; that tumors on the interior
aspects of the lungs and in mediastinal lymph nodes are not
quantified; and most importantly, each measurement of
tumor burden requires sacrifice of the animal, precluding
analysis of responsiveness to therapeutic endeavors. This1These authors contributed equally to this work.
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results in experiments that require unnecessarily large num-
bers of animals in order to monitor tumor load at different
time points. The ability to monitor the number and anatomic
location of living tumor cells sequentially in a live animal can
address all of these deficiencies.
Lastly, melanoma commonly metastasizes to the brain in
humans. Patients with brain metastases are typically con-
sidered for palliative care only because of the high risk of
complications during interventional therapies, as well as a
perceived risk for inducing CNS autoimmunity. Therefore,
significant research efforts are targeted at developing ther-
apies for melanoma metastases to the brain. Monitoring of
brain tumor development in animals is complicated by
some of the same challenges outlined for lung metastases
above. Brain tumor burden is, however, usually monitored
indirectly through morbidity and survival curves. This meth-
odology requires increased numbers of experimental ani-
mals and does not directly quantify tumor burden in the
brain. Nor does it account for other causes of mortality (i.e.,
inflammatory responses that induce increased intracranial
pressure). Post-mortem dissection is the most commonly
used means to quantify intracranial tumors. The ability to
monitor intracranial tumor growth in live animals would aid
in the assessment of potential therapies for intracranial me-
lanoma metastases.
Currently available technologies to study tumors in live
rodents include MRI (magnetic resonance imaging), micro-
CT (computed tomography) micro-PET (positron emission
topography), and bioluminescent imaging (BLI). MRI, CT,
and PET all offer the advantage of more accurate three-
dimensional structural imaging of tumor mass and all can be
used on tumors of endogenous origin. Additionally micro-
PET offers the ability to image biological processes with
molecular, enzymatic, or metabolic endpoints. MRI, CT, and
PET are all quite expensive to perform, require significant
image collection time, and can only image one animal at a
time. BLI offers the advantage of being relatively inexpen-
sive, has a very short image collection time, many animals
can be imaged simultaneously, is quite sensitive, and the
equipment is readily available (Xenogen, Alameda, Califor-
nia) The disadvantage of the BLI system is that it currently
does not have as high of a resolution as the above tech-
niques, and the system collects tumor signal in a two-
dimensional plane. Additionally, BLI depends on the
expression of a foreign gene in the tumors being evaluat-
ed thus limiting its use in endogenous tumors. (Reviewed in
Contag and Ross (2002) and Hollingshead et al (2004).)
The advantages of BLI outweigh the advantages of other
tumor assessment modalities in this system. Thus, we
sought to develop and characterize a mouse melanoma
model using BLI where serial monitoring allows for accu-
rate, real time, in vivo, quantification of tumor burden. The
A375 melanoma cell line has been previously used to study
imaging techniques (Ray et al, 2004). In this report, we
characterize a novel murine model using the B16 tumor line
expressing firefly luciferase (Fluc) and green fluorescent
protein (GFP) demonstrating its accuracy and utility for
subcutaneous tumors, lung metastases, and intracranial
tumor monitoring and show examples of each. We show
this technology is not limited to the B16 line by extending
our studies to the A375 human melanoma line in SCID mice.
The B16-Fluc model has been successfully used recently by
our group to study vaccine therapy, (Bruhn et al, 2005) and
vaccine adjuvants.2 Additionally, we have also used the
A375-Fluc model to study direct tumor therapies targeting
cell signaling cascades in melanoma (Collisson et al, 2003a,
b). Because these models offer many advantages over tra-
ditional models of tumor monitoring and limit the number of
animals required for preclinical studies of potential thera-
pies, these BLI models should be considered in future
studies of melanoma and may be extended to other me-
lanoma models and other tumor models in general when
possible.
Results and Discussion
Quantification of metastatic tumors by lung examination
offers only a gross estimate of tumor burden, as individual
lung nodules tend to vary widely in size, density, and loca-
tion. This methodology also requires euthanasia and allows
analysis at only a single time point. To circumvent these
limitations, we used optical imaging of bioluminescent
tumor cells as an alternative approach to assess levels of
systemic immunoprotection. B16 melanoma cells were sta-
bly transduced with a lentiviral construct expressing the
Fluc and GFP coding sequences (Ray et al, 2004). These
cells were introduced back into C57BL/6 mice, either by
subcutaneous injection, by intravenous injection, or by in-
tracranial implantation. To visualize B16-Fluc cells in the
animals, we injected the luciferase substrate D-luciferin into
the peritoneum of anesthetized animals and detected bio-
luminescence with a cooled charge-coupled device (CCD)
camera (Wu et al, 2001). Examples of mice with subcuta-
neous tumors (Fig 1A), lung tumors (Fig 1B), and intracranial
tumors (Fig 1C) are shown. The colors overlying the animals
represent the rate of photons being emitted where red is the
highest density of photons and violet is the lowest detect-
able emission rate.
To characterize the imaging system with B16 tumors and
validate our results, we correlated rates of photon emission
with tumor burden. As shown in Fig 2A, light emission as
detected by the imaging system correlates well with number
of B16-Fluc cells in a 50 mL droplet in vitro. The correlation is
linear at very low and at high levels (r2¼0.99) of lumines-
cence (Fig 2). Notably, the limits of detection ex vivo are not
fully tested here since several parameters including dis-
tance to the detector and substrate concentration were not
varied. When serial dilutions of cells were imaged 30 min
following intravenous injection, photon emission correlated
well (r2¼0.92) with number of cells injected (Fig 3A). Al-
though the number of cells retained in the lungs immediately
after injection cannot be determined, these results indicate
that the lower limit for detection of B16-Fluc lung met-
astases may be approximately 1  104 B16 Fluc cells. This
limit of detection is dependent on several factors including
cell line, expression construct, concentration of luciferin in-
jected, the light collecting efficiency of the imaging system,
and distance from the animal to the detector. This example
2N. Craft et al, The toll-like receptor 7 agonist imiquimod
enhances the anti-melanoma effects of a recombinant Listeria
manocytogenes vaccine. Manuscript submitted.
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is shown to illustrate the linear nature of the system and the
lower limits of detection using typical settings with this par-
ticular B16-Fluc model. After 11 d, these animals were eu-
thanized and their lungs were excised. BLI measurements
also correlated with the numbers of surface metastases on
excised lungs upon ex vivo visual examination of the lungs
(Fig 4). This example illustrates why visual inspection of lung
metastases is a very crude assessment of metastatic tumor
volume and that BLI assessment of lung metastases is more
accurate at very low and very high tumor burdens.
To determine the total tumor burden in the lungs, the
lungs were homogenized and total luciferase activity was
determined with luminometry of the cell lysate. The in vivo
BLI measurements correlated well with the ex vivo total
luciferase activity (Fig 3B, r2¼0.98). Photon emission is at-
tenuated exponentially through animal tissue making de-
tection from the lungs more challenging. In similar pilot
studies, we were able to detect as few as 500 B16-Fluc
cells subcutaneously by BLI (not shown). Notably, this sys-
tem is sensitive enough to detect growth of the B16-Fluc
cells left in the needle track after intravenous injection into
the tail vein for lung metastases three weeks earlier (Fig 1B).
There were no palpable tumors in the area of tail involved
(not shown).
As proof of principal, we utilized BLI methodology to
measure systemic protection against melanoma tumor
Figure 1
Three distinct models of B16-Fluc (fire-
fly luciferase) murine melanoma analy-
zed with bioluminescent imaging. Note
signal scale differences and magnification
differences between panels. (A) 1  104
cells were implanted subcutaneously in
100 mL with 50% Matrigel and imaged for
5 s 3 wk after implantation. (B) 1  104
cells were injected intravenously in 200 mL
PBS and imaged for 60 s 3 wk later to
show metastases in the lungs. Note signal
from needle track in tails where injection
was made 3 wk prior, detecting a very
small number of viable cells in the tail. (C)
1  103 cells in 2 mL were implanted in-
tracranially with a Hamilton syringe and
imaged 2 wk later for 60 s (signal ob-
served on ears is reflective light).
Figure 2
Bioluminescence correlates with in
vitro cell number. B16-Fluc (firefly lucif-
erase) cells were counted, serially diluted,
and then mixed with D-luciferin substrate
in a 50 mL droplet. Droplets were imaged
immediately afterwards for 60 s. (A) Bio-
luminescent signal (photons per s per cm2
per steridian) correlates linearly with cell
number. (B) Representative images from
droplets of the serial dilution.
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growth over time following immunotherapy with a live re-
combinant Listeria monocytogenes (rLM) vaccine express-
ing the melanoma antigen tyrosinase-related protein (TRP-
2). Protection by this rLM vaccine against subcutaneous
B16 tumor challenge with tumor burden assessed by stand-
ard caliper measurements is reported by our group else-
where.2 After primary immunization and boost with either
LM-NP (control listeria expressing only the viral epitope NP)
or LM-TRP2-NP (active vaccine expressing both viral NP
and TRP-2), mice were intravenously challenged with B16-
Fluc cells 2 wk later. Mice were then imaged at various
times post challenge. Day 15 measurements revealed rel-
atively low bioluminescent signals in both groups (Fig 5A).
By day 21, however, control LM-NP-immunized mice dis-
played a 10-fold higher luciferase signal in their lungs than
LM-TRP2-NP-immunized mice (Fig 5A, B) (po0.005). Sim-
ilar results have been observed for subcutaneous tumor
growth of B16-Fluc (not shown). Additionally, similar results
are seen using B16 cells not expressing Fluc.2 These results
demonstrate the ability of a live Listeria vaccine expressing
the melanoma-associated antigen TRP-2 to protect mice
from systemic challenge with the B16-Fluc melanoma cell
line. Additionally, this study demonstrates that serial BLI
provides a valuable tool for evaluating immunotherapeutic
efficacy in mice repeatedly and quantitatively over time. As
this technology becomes more widely available and the re-
sults are validated by others, BLI may offer a more sensitive
and reproducible alternative to visual inspection as an as-
sessment of lung tumor volume and therapies targeting
melanoma metastasis in the B16 model.
Since GFP and luciferase may represent neoantigens in
the mouse (Gambotto et al, 2000; Murakami et al, 2003), it is
possible that introduction of these reporter genes may lead
to natural immunogenicity and rejection of B16-Fluc tumors.
Other BLI tumor models, however, have not found a dif-
ference in tumor formation between parental lines and
those expressing the reporter genes (Smakman et al, 2004).
Based on several findings, it is unlikely that immunogenicity
to these reporter genes is occurring to a significant degree
in our model: (1) subcutaneous implantation of the B16-Fluc
cell line leads to tumor formation at an equal or slightly
faster rate than the parental cell line in prior experiments; (2)
mice implanted with both cell lines became moribund at
equal rates when the cells were implanted intracranially;
and (3) in the absence of immunotherapy, no significant in-
flammatory infiltrate has been detected in B16-Fluc tumors
histologically.
Figure3
Bioluminescence correlates with tumor volume in
vivo. (A) Varying numbers of B16-Fluc (firefly luciferase)
cells were injected intravenously into the tail vein and
the mice were imaged 30 min later to detect tumor cells
in the lungs. Bioluminescent signal (photons per s per
cm2 per steradian) correlates with cell number implant-
ed. These mice were kept for 11 d and then imaged
again on day 11. Lungs were then excised, homogen-
ized, and total luciferase activity was determined with a
standard ex vivo luciferase assay. (B) Total ex vivo lucif-
erase activity correlates with day 11 bioluminescence
in vivo. (C) After immunization with a live Listeria vaccine
(see Fig 5), mice were challenged with 1  104 B16-Fluc
cells intravenously and then imaged 3 wks later to detect
lung metastases. These lungs were then excised and ex
vivo luciferase activity determined. Total ex vivo lucif-
erase activity correlates with day 21 bioluminescence
in vivo after immunization against the tumor.
Figure 4
Bioluminescence correlates with ex vivo visual assessment of
tumor volume. Mice were challenged with varying numbers of B16-
Fluc (firefly luciferase) cells intravenously and imaged 11 d later to de-
tect lung metastases. Example comparisons of bioluminescent signals
with ex vivo visualization is demonstrated.
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To further characterize the relationship between tumor
burden and photon emission, we measured photon emis-
sion rates from 3-wk-old tumors that had been established
in the lungs after mice were immunized with the live Listerial
vaccine or control vaccine (see above). Although, there was
slightly more variability, measuring rates of photon emission
detected B16-Fluc cells in the lungs in vivo, we observed a
high correlation (r2¼0.89) with the amounts of total lucif-
erase activity measured by traditional in vitro luminometer
assays on homogenized tumor-bearing lungs (Fig 3C).
These findings suggest that tumor therapies, whereas af-
fecting the total tumor burden, do not affect the correlation
of BLI measurements in this model with total tumor burden.
Additionally, since the reaction that produces photons re-
quires oxygen, ATP, luciferase, and the substrate D-luciferin,
BLI detects only vascularized, viable tumor cells and thus
accounts for necrotic or dying tumor regardless of the
cause. As quickly growing tumors may, however, have areas
of hypoxia where the tumor cells are still viable, BLI meas-
urements could be influenced by the degree of tumor per-
fusion and oxygenation. Additionally, the sharp dependence
of signal strength on tumor depth makes imaging in larger
animals more challenging.
Intracranial tumor growth is particularly challenging to
monitor in live animals given the confines of the skull. Thus,
we extended our studies to the intracranial B16 model. B16-
Fluc cells were implanted as described in methods and live
mice were serially monitored with BLI over 3 wk. An exam-
ple of intracranial tumor enlargement in a group of five mice
over the 3 wk is shown (Fig 6). When mice are examined
over the last week it is clear that animals with larger tumors,
as measured by BLI, become moribund earlier than mice
with smaller tumors. This was also reflected in their survival
(data not shown). BLI has been used to study intracranial
viral infections (Luker et al, 2002), and other intracranial
tumors (Rehemtulla et al, 2000) but, this is an example of
the ability to use BLI to monitor intracranial B16 murine
melanoma tumors in live animals. Animal ‘‘survival’’ may
represent multiple factors including tumor size, intracerebral
inflammation, location of tumor, or confounding infections.
Thus, BLI assessment of intracranial tumors may offer sig-
nificant advantages for pure evaluation of intracranial tumor
size when compared to animal survival.
To extend these studies to another melanoma model, we
transduced two clones of the human A375 melanoma cell
line with a lentiviral construct expressing hRL in place of
Fluc. A375, being a heterologous human tumor cell line
must be grown in immunocompromised mice. Two sub-
lines of A375 represent the parental cell line (A375P) and a
highly metastatic sub-line (A375M) derived by serial pas-
sage of the tumor through tail vein injections and isolation of
pulmonary metastases (Clark et al, 2000). Transduced cells
were selected for high GFP expression by fluorescence ac-
tivated cell sorting. High GFP-expressing populations were
injected into the tail vein of SCID mice and serially imaged
using BLI. Two representative mice are shown for each sub-
line (Fig 7A). On day 0, 30 min after injection, most injected
cells are trapped within the pulmonary capillaries and sim-
ilar signals can be seen from the two sub-lines. On day 1,
detectable signal is lost from the lungs showing clearance
Figure 5
Live Listeria vaccine expressing ty-
rosinase related protein-2 protects
mice from systemic B16 melanoma
challenge, as quantified by biolumi-
nescent imaging. C57BL/6 mice were
immunized and boosted with recombin-
ant Listeria monocytogenes (rLM) ex-
pressing the LCMV NP396–404 epitope
(LM-NP) or the NP396–404 epitope and
the melanoma antigen TRP2180–188 epi-
tope (LM-TRP2-NP) and challenged in-
travenously with 1  104 B16-Fluc
(firefly luciferase) cells 2 wk later. Tumor
fluorescence from B16-Fluc tumors was
quantified as described in methods at
various time points. (A) Graph repre-
sents the mean of seven mice per group
each compared to control growth on
day 15 and day 21 (meanþSEM). On day 15, there was low signal from most mice and no significant difference between the groups. By day 21,
however, large differences between the experimental and control groups can be seen. (po0.005) (B) Representative images of mice are shown on
day 21.
Figure 6
Bioluminescent imaging to monitor in-
tracranial tumor volume. Mice were im-
planted into the striatum with 1  103 B16
firefly luciferase (Fluc) cells in 2 mL PBS
with a Hamilton syringe and imaged seri-
ally for 3 wk. Representative images are
shown on days 8, 14, and 20. Note one
mouse was euthanized from this group
due to the development of neurological
deficits prior to the day 20 image.
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of almost all of the tumor cells injected. By day 24, it is clear
that the metastatic variant of this cell line has formed more
tumors in the lungs of these SCID mice. By day 31, a focus
of tumor in the liver can be clearly identified in one mouse
injected with the metastatic sub-line. In these A375 cell
lines, the expression of GFP from the integrated lentiviral
construct (hRL-IRES-GFP) is greater than in the B16 model
(Fluc-IRES-GFP) (not shown). Because of the increased
signal intensity, it is possible to visualize the tumor nodules
on the lungs of these mice ex vivo using blue light illumi-
nation, GFP appropriate emission filters, and detection with
a standard digital CCD camera. Increased metastatic foci
are seen in the lungs excised from representative mice (from
panel A) challenged with the metastatic sub-line, A375M
compared with the parental line A375P (Fig 7B). The in-
creased signal intensity on the flank of the A375P mouse on
day 39, likely represents contamination with phosphores-
cent material. This is also seen on the snouts and forepaws
of several animals. This signal may also represent an occult
visceral or lymph node metastasis, but this could not be
confirmed visually at necropsy. These signals however, do
not affect the tumor evaluation in the lungs since flux cal-
culations are limited to a region of interest drawn over the
lungs using the imaging software.
One area of potential application is to use hRL and Fluc
in the same cells. This would overcome the barriers of hav-
ing to use other colors for monitoring with shorter wave-
lengths, which are more easily absorbed by tissue. Renilla
has a shorter wavelength than Fluc, so is better to use if the
object of interest is on the surface of the animal. Addition-
ally, the renilla substrate has a shorter half-life. Thus, one
can measure both renilla and Fluc in the same animal in the
same tumor at times very close to one another.
These results suggest that BLI technology may be useful
in multiple human and murine tumor models. Although the
existing models of B16 metastasis do not reflect all of the
naturally occurring steps of true metastasis, they provide
useful methods to assess effects of therapies on systemic
melanoma burden and intracranial tumors. The addition of
BLI to these models will be useful for studies that are im-
munologically based, therapies targeting tumors directly, or
studies investigating metastatic mechanisms of melanoma
cells in immunocompromised mice with human tumors. Al-
though this technology requires a sophisticated imaging
system, the overall advantages of BLI combined with the
benefits of decreased animal and husbandry costs may
outweigh the initial financial setback of purchase.
Materials and Methods
Bacterial and mouse strains Female C57Bl/6 (H-2b MHC) mice
were purchased from Jackson Laboratories (Bar Harbor, Maine)
and were between 6 and 10 wk and age-matched before initiation
of experiments. Beige SCID were used for studies involving the
A375 human melanoma line. Listeria monocytogenes 10403S (LM)
(Baldridge et al, 1988) (serotype 1/2a, obtained from David Hin-
richs, Veterans Affairs Medical Center, Portland, Oregon, via Daniel
Portnoy) was the virulent parental bacterial strain used for all re-
combinant constructs, and was grown and maintained in brain–
heart infusion (BHI) broth or on agar plates with streptomycin (200
mg per mL) selection. Recombinant LM strains LM-NP and LM-
TRP2-NP expressing the LCMV NP396–404 epitope (both strains)
and TRP2180–188 (only LM-TRP2-NP) under control of the LM hly
listeria promoter and containing the hly signal sequence were cre-
ated as previously described.2
Immunization of mice C57Bl/6 mice (6–10 wk old) were inocu-
lated in the tail vein with 0.1 LD50 of each rLM strain (see Fig 1) in
200 mL of phosphate-buffered saline (PBS), using 28 gauge nee-
dles. Boosting immunizations were given 2–3 wk later, at a dose of
Figure 7
Bioluminescent imaging of metastatic differences in clones of
human melanoma in severe combined immunodeficiency mice
(SCID) mice. SCID mice were challenged with 1.2  106 A375 parental
(A375P) or A375 metastatic clone (A375M) cells intravenously and se-
rially imaged. (A) Representative examples of these mice are shown
throughout the experiment. Minutes after tumor challenge, similar
numbers of cells are seen in the lungs and circulatory systems of these
mice. By day 3, both lines are undetectable. In the highly metastatic
line, detectable tumors arise in the lungs after 3 weeks. (B) This dif-
ference is corroberrated at necropsy by visualization of the green flu-
orescent protein expressing tumor nodules in the lungs, where the
highly metastatic line A375M has formed a far greater number of lung
metastases than the parental line A375P.
164 CRAFT ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
1.0 LD50. All studies were carried out with the approval of the UCLA
Animal Research Committee (ARC).
Cell lines The B16 murine melanoma cell line was obtained from
the ATCC (Rockville, Maryland) and maintained in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% fetal calf serum (FCS),
Pen/Strep and L-glutamine. Prior to tumor challenge, B16 cells
were grown in supplemented DMEM, harvested, washed three
times, and resuspended in PBS. The A375 parental cell (A375P)
line was maintained in DMEM with 10% FCS, Pen/Strep and L-
glutamine. The A375 metastatic cell line (A375M) was derived by
three serial passages consisting of mouse tail vein injection and
isolation of pulmonary metastases as described (Clark et al, 2000).
Statistical analysis All error bars represent standard error of
the mean unless otherwise designated. Significant differences of
tumor growth were assessed by Student’s t test. The difference
between groups was considered statistically significant when the p
value was lower than 0.05.
Optical imaging of bioluminescent tumors and in vitro lucif-
erase assay B16 tumor cells were transduced with a lentiviral
construct containing the Fluc gene and the GFP gene, separated
by an encephalomyocarditis virus internal ribosomal entry site, and
driven by an internal CMV promoter. Stable cell lines were selected
by flow cytometry sorting for cells with high levels of GFP expres-
sion. We refer to the stable luciferase-expressing cell line used as
B16-Fluc. Growth rates of B16-Fluc both in vitro and in vivo were
similar to those of parental B16 cells.
The A375P and A375M cell lines were transduced with a lenti-
viral construct containing the hRL gene and the GFP gene, sep-
arated by an encephalomyocarditis virus internal ribosomal entry
site, and driven by an internal CMV promoter. Stable cell lines were
selected by flow cytometry sorting for cells with high levels of GFP
expression.
For intravenous challenges, cells were washed and resuspend-
ed in PBS at various concentrations and 200 mL were injected via
the tail vein. The standard B16-Fluc tumor challenge dose for
immunotherapy experiments is 1–2  104 cells. 1.2  106 A375P
or A375M cells were injected for comparison metastasis studies.
For subcutaneous tumors, cells were resuspended at various con-
centrations in PBS and diluted 1:1 with Matrigel (BD Biosciences,
Bedford, Massachusetts). After anesthesia, mice were injected
subcutaneously into the shaved flank with 100 mL of this mixture
using a 28 guage needle. The standard tumor challenge dose is
1  104 cells. For intracranial implantation, mice were anesthetized
with ketamine:xylazine and 1  103 cells in a volume of 2 mL PBS
were implanted into the striatum as previously described (Prins
et al, 2004) using a Hamilton syringe.
Prior to imaging, mice were anesthetized with a cocktail of
ketamine:xylazine (4:1) in PBS. For B16 cells expressing Fluc, mice
were injected intraperitoneally with 100 mL of 30 mg per mL of the
luciferase substrate, D-luciferin (Xenogen) in PBS, and shaved over
the tumor site to minimize the amount of light absorbed by black
fur and imaged after 10–15 min. For A375 cells expressing hRL,
mice were injected via the tail vein with 10 mL (2 mg per mL dis-
solved in methanol) of coelenterazine (Biotium, Hayward, Califor-
nia) diluted with 90 mL PBS (pH 7). The mice were then placed in a
light tight chamber and a cooled CCD camera apparatus (IVIS,
Xenogen) was used to detect photon emission from tumor-bearing
mice with acquisition times ranging from 1 s to 2 min. Analyses of
the images were performed as described previously (Wu et al,
2001; De et al, 2003) using Living Image software (Xenogen) and
Igor Image analysis software (Wave Metrics, Lake Oswego, Ore-
gon) by drawing regions of interest over the tumor region and
obtaining maximum values in photons per second per cm2 per
steradian or total flux as photons per second.
Ex vivo GFP expressing lung tumors were visualized within
30 min using blue light excitation and GFP appropriate emission
filters. Photographs were taken with a standard CCD camera
(Nikon Coolpix 4500, Nikon, Melville, New York).
In vitro luciferase activity was determined by homogenization of
the lung tissue through nylon mesh and freeze–thaw lysis in buffer
provided with the luciferase kit (Promega, Madison, Wisconsin).
Samples were combined with D-luciferin substrate as directed in the
product instructions and relative light units determined in a bench
top luminometer.
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